SCHEDULE: Coastlands Capital Discloses 14.22% Stake in Adial Pharmaceuticals

Coastlands Capital LP and affiliated entities have reported beneficial ownership of 14.22% of Adial Pharmaceuticals' common stock, totaling 373,322 shares.

Summary

• Coastlands Capital LP, along with its affiliates Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, have jointly filed a Schedule 13G, indicating their beneficial ownership of Adial Pharmaceuticals, Inc. common stock.
• The reporting persons collectively own 373,322 shares of common stock, representing 14.22% of the class.
• This ownership is based on 2,625,943 shares outstanding as of June 17, 2026, as provided by Adial Pharmaceuticals.
• The filing explicitly excludes pre-funded warrants held by the Reporting Persons that exceed a beneficial ownership limitation of 4.99%.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard disclosure of a significant passive investment stake, with no immediate positive or negative financial performance indicators or strategic shifts mentioned.

Positives

• Significant ownership stake of 14.22% by Coastlands Capital and its affiliates, indicating substantial investor interest.
• The filing confirms that the shares were acquired and are held in the ordinary course of business, suggesting a non-activist investment approach.

Negatives

• The exclusion of pre-funded warrants exceeding 4.99% ownership limitation suggests potential for future increases in beneficial ownership, which could be viewed with caution by existing shareholders if not managed transparently.
• The filing does not provide details on the acquisition cost or strategy behind this stake, leaving room for speculation.

Risks

• Potential for future increases in beneficial ownership beyond the current 14.22% if pre-funded warrants are exercised, which could impact share price and control dynamics.
• The lack of explicit detail regarding the purpose of the investment beyond 'ordinary course of business' could be interpreted as a potential risk if the investor's intentions shift.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Adial Pharmaceuticals. The future outlook is primarily shaped by the reporting persons' stated intention to hold securities in the ordinary course of business, while also noting the potential for increased ownership through pre-funded warrants.

Management Comments

• Each reporting person disclaims membership in a group and beneficial ownership except to the extent of their pecuniary interest.
• The filing of this Schedule 13G should not be construed as an admission that the Partnership is a beneficial owner of any Common Stock covered by this Schedule 13G.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. However, the significant percentage reported by Coastlands Capital, coupled with the mention of pre-funded warrants, suggests a notable position that warrants monitoring for any potential shift towards a more active role or increased influence in Adial Pharmaceuticals.

Stakeholder Impact

• Shareholders: The increased concentration of ownership by a single entity may influence future corporate actions or strategic decisions.
• Management: May need to engage with Coastlands Capital regarding their investment strategy and potential influence.
• Potential Investors: The filing provides transparency on a significant shareholder, aiding in investment analysis.

Next Steps

• Monitor future filings from Coastlands Capital and its affiliates for any changes in beneficial ownership.
• Observe Adial Pharmaceuticals' stock performance and strategic announcements for potential correlation with this significant shareholder's position.

Key Dates

Keywords

Schedule 13G, Adial Pharmaceuticals, Coastlands Capital, Beneficial Ownership, Common Stock, SEC Filing, Investment, Securities Exchange Act